EVGN icon

Evogene

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 100%
Negative

Neutral
PRNewsWire
4 days ago
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity REHOVOT, Israel, June 2, 2026 /PRNewswire/ -- Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, today announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biomica Ltd.
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
Neutral
Seeking Alpha
8 days ago
EverGen Infrastructure Corp. (EVGN:CA) Q1 2026 Earnings Call Transcript
EverGen Infrastructure Corp. (EVGN:CA) Q1 2026 Earnings Call Transcript
EverGen Infrastructure Corp. (EVGN:CA) Q1 2026 Earnings Call Transcript
Neutral
Seeking Alpha
17 days ago
Evogene Ltd. (EVGN) Q1 2026 Earnings Call Transcript
Evogene Ltd. (EVGN) Q1 2026 Earnings Call Transcript
Evogene Ltd. (EVGN) Q1 2026 Earnings Call Transcript
Neutral
PRNewsWire
17 days ago
Evogene Reports First Quarter 2026 Financial Results
Conference call and webcast: today, May 20, 2026, 9:00 AM ET REHOVOT, Israel, May 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the first quarter ended March 31, 2026.
Evogene Reports First Quarter 2026 Financial Results
Neutral
PRNewsWire
25 days ago
Evogene to Present at the 24th Schrödinger European User Group Meeting
Conference will be held in Munich, Germany - May 19-21, 2026 REHOVOT, Israel, May 12, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its participation in the 24th Schrödinger European User Group Meeting, taking place May 19–21, 2026, in Munich, Germany.
Evogene to Present at the 24th Schrödinger European User Group Meeting
Neutral
PRNewsWire
1 month ago
Evogene Schedules First Quarter 2026 Financial Results Release
Zoom conference call scheduled for May 20, 2026, 9:00 AM ET REHOVOT, Israel, May 7, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the first quarter 2026, on Wednesday , May 20 , 2026.
Evogene Schedules First Quarter 2026 Financial Results Release
Neutral
Seeking Alpha
1 month ago
EverGen Infrastructure Corp. (EVGN:CA) Q4 2025 Earnings Call Transcript
EverGen Infrastructure Corp. (EVGN:CA) Q4 2025 Earnings Call Transcript
EverGen Infrastructure Corp. (EVGN:CA) Q4 2025 Earnings Call Transcript
Neutral
PRNewsWire
2 months ago
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
REHOVOT, Israel, April 2, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN)(TASE: EVGN) (the "Company", "Evogene"), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today reported that the Company received a letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company is currently not in compliance with Nasdaq Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares has been below $1.00 per share for 30 consecutive business days.
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
Neutral
PRNewsWire
2 months ago
Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock
Today, castor oil is a premium sustainable industrial feedstock for bio-based products REHOVOT, Israel, March 31, 2026 /PRNewswire/ -- Casterra Ag Ltd. ("Casterra"), a developer of high-yield castor seed varieties and integrated castor farming solutions, and a subsidiary of Evogene Ltd.
Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock
Neutral
PRNewsWire
2 months ago
Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026
Conference will be held at Lisbon, Portugal - March 23–25, 2026 REHOVOT, Israel, March 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced it will be featured as a presenting company at the upcoming BIO-Europe Spring 2026 conference, being held on March 23-25, in Lisbon.
Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026